Motley Fool Wealth Management LLC Sells 7,231 Shares of Kenvue Inc. $KVUE

Motley Fool Wealth Management LLC lessened its holdings in Kenvue Inc. (NYSE:KVUE) by 12.5% in the second quarter, Holdings Channel reports. The institutional investor owned 50,387 shares of the company’s stock after selling 7,231 shares during the period. Motley Fool Wealth Management LLC’s holdings in Kenvue were worth $1,055,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Evergreen Wealth Solutions LLC raised its holdings in Kenvue by 2.6% in the 1st quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company’s stock valued at $402,000 after buying an additional 432 shares during the last quarter. Wealth Alliance LLC raised its holdings in Kenvue by 1.6% in the 1st quarter. Wealth Alliance LLC now owns 31,778 shares of the company’s stock valued at $762,000 after buying an additional 486 shares during the last quarter. Everett Harris & Co. CA raised its holdings in Kenvue by 1.4% in the 1st quarter. Everett Harris & Co. CA now owns 36,971 shares of the company’s stock valued at $887,000 after buying an additional 500 shares during the last quarter. Proffitt & Goodson Inc. raised its holdings in Kenvue by 8.2% in the 2nd quarter. Proffitt & Goodson Inc. now owns 6,831 shares of the company’s stock valued at $143,000 after buying an additional 517 shares during the last quarter. Finally, UMB Bank n.a. raised its holdings in Kenvue by 22.3% in the 2nd quarter. UMB Bank n.a. now owns 2,853 shares of the company’s stock valued at $60,000 after buying an additional 521 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on KVUE. Jefferies Financial Group dropped their price objective on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating for the company in a report on Monday. Barclays dropped their price objective on shares of Kenvue from $20.00 to $17.00 and set an “equal weight” rating for the company in a report on Wednesday, October 1st. Bank of America decreased their target price on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, October 8th. Zacks Research raised shares of Kenvue to a “strong sell” rating in a research report on Monday, August 11th. Finally, Rothschild Redb raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, September 26th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and a consensus price target of $20.90.

Kenvue Stock Performance

NYSE:KVUE opened at $14.49 on Wednesday. The company has a market capitalization of $27.80 billion, a PE ratio of 19.57, a P/E/G ratio of 2.18 and a beta of 0.72. The company has a 50 day simple moving average of $17.64 and a two-hundred day simple moving average of $20.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. Kenvue Inc. has a fifty-two week low of $14.05 and a fifty-two week high of $25.17.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.01. The business had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company’s revenue for the quarter was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.